HIGHLIGHTS
- who: Jiaqi Hui et al. from the Laboratory of Cardiovascular Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China have published the research work: Efficacy and Safety of Different Courses of Tongxinluo Capsule as Adjuvant Therapy for Coronary Heart Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, in the Journal: (JOURNAL) of 26/08/2021
- what: In the present study, published reports of clinical trials about TXLC as the adjuvant therapy were collected comprehensively and systematically, and the efficacy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.